Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
13 avr. 2022 09h00 HE
|
Allogene Therapeutics, Inc.
Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic MalignanciesALLO-316, in Phase 1 TRAVERSE Trial for the Treatment of Renal Cell Carcinoma, Granted Fast...
Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
12 avr. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
23 mars 2022 08h30 HE
|
Allogene Therapeutics, Inc.
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing ActivityPhase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the...
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
10 mars 2022 08h30 HE
|
Allogene Therapeutics, Inc.
ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which Has Broad Potential Application Across a Variety of Solid Tumors and Hematologic MalignanciesPhase 1 TRAVERSE Trial of ALLO-316...
Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
01 mars 2022 08h30 HE
|
Allogene Therapeutics, Inc.
Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
23 févr. 2022 16h02 HE
|
Allogene Therapeutics, Inc.
AlloCAR T™ Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022Phase 1 Data from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma...
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
16 févr. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
26 janv. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
11 janv. 2022 08h00 HE
|
Allogene Therapeutics, Inc.
miCAR Platform Enables Simultaneous Silencing of Multiple Gene TargetsAllogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products SOUTH SAN FRANCISCO,...
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
10 janv. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
Investigation Confirmed the Chromosomal Abnormality in a Single Patient was Not Observed in Any AlloCAR T Product and Not Related to Allogene Manufacturing Process or TALEN® Gene EditingClinical...